Is Human vaccines & immunotherapeutics SCI Indexed? Indexing Status & Metrics

Journal Citation Impact

Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.

Impact Factor

4.19

Citation rate 4.84 4,740 total citations

h5-index 66 h5 depth signal

Cited share 79.3% 849 of 1,070

Total citations 4,740 Citation footprint

Metric signal 4.57 External metric anchor

Self-citation 7.4% 351 self-citations

Citations Trend

Monthly Publications Cadence

Citing Geographic Demographics

China 1,370

United States 1,312

Italy 371

United Kingdom 289

Canada 272

Citing Fields of Research

Virology 1,612

Immunology 1,236

Oncology 920

Health Education & Remote Healthcare 797

Healthcare Policy 676

Publishing Activity & Reach

Volume, recency, access pattern, and citing-community signals from the journal analytics record.

All-time article footprint 7,231 Articles tracked across the journal lifetime

Indexed publication set 1,070 849 cited publications

Last 12 months 550 45.8 publications/month

Open access share 99.5% 547 OA publications in the last year

Leading citing country China 1,370 citing publications

Leading citing field Virology 1,612 citing publications

Latest tracked publication 16 October 2026 10 recent records available

Coverage & Indexing History

MEDLINE

v8n1, Jan. 2012-

PubMed

v8n1, Jan. 2012-

PMC

Active Coverage

Research Focus & Classification

Indexed Subjects

Virology Oncology Immunology Antibiotic & Antibacterial Agents Health Education & Remote Healthcare

Broad Categories

Allergy and Immunology Virology

MeSH Descriptors

Immunotherapy Vaccines

Latest Publications

Recent article records with DOI-first linking and condensed abstracts.

01 16 October 2026

DOI 10.1080/21645515.2026.2738264

HPV vaccination coverage and barriers for people with disability: A scoping review

Open DOI

Sarah Walmsley, Claire M. Vajdic, Glenda M. Bishop et al.

02 15 October 2026

DOI 10.1080/21645515.2026.2728535

Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trial

Open DOI

Anahita Fathi, Christine Dahlke, Leonie Mayer et al.

03 14 October 2026

DOI 10.1080/21645515.2026.2744469

Safety signals of tocilizumab in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database with network pharmacology insights

Open DOI

Gang Wu, Xueqing Ma, Bin Zhu et al.

04 14 October 2026

DOI 10.1080/21645515.2026.2745402

RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024

Open DOI

Vishal Saundankar, Reiko Sato, Robyn Moucka et al.

05 13 October 2026

DOI 10.1080/21645515.2026.2746289

Development of mRNA vaccines against herpes zoster

Open DOI

Dongdong Li, Jun Luo, Junwei Wang et al.

Varicella-zoster virus (VZV), also designated as human herpesvirus 3 (HHV-3), is a double-stranded DNA virus belonging to the Alphaherpesvirinae subfamily, which also includes Herpes simplex virus ...

06 9 October 2026

DOI 10.1080/21645515.2026.2739001

Safety of nirsevimab in children aged 0–24 months: Analysis based on EudraVigilance data (2023–2025)

Open DOI

Cristina Morciano, Arianna Annunziata, Maria Cutillo et al.

07 8 October 2026

DOI 10.1080/21645515.2026.2743369

Balancing individual risks and collective benefits: Effects of vaccine price, message framing, and value orientations on influenza vaccination in China

Open DOI

Yili Chu, Ye Jiang, Qingqing Cheng et al.

Influenza is a highly contagious and rapidly mutating respiratory disease, causing about 1 billion cases, 3–5 million severe cases, and 290,000–650,000 respiratory deaths worldwide annually.1 Influ...

08 8 October 2026

DOI 10.1080/21645515.2026.2741765